All News
Filter News
Found 808,532 articles
-
Centivax Antibodies Neutralize the Pandemic Coronavirus, Independently Confirmed by Three Research Laboratories (USAMRIID, Stanford, and UTMB/GNL)
5/18/2020
Centivax Inc, the therapeutics spin-out of Contract Research Organization Distributed Bio Inc, announced a significant advance in their mission to develop an optimized antibody therapeutic to treat COVID-19.
-
Centene Corporation To Host Virtual Investor Meeting On June 12, 2020
5/18/2020
Centene Corporation (NYSE: CNC) today issued a press release announcing that it will host an investor meeting, in a virtual format, on Friday, June 12, 2020 . Michael F. Neidorff , Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke , Executive Vice President and Chief Financial Officer, of Centene Corporation will h
-
Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting
5/18/2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting participants, the location and format of its 2020 Annual Stockholder Meeting
-
Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests
5/18/2020
Sub-distributor has network of state and local government clients seeking testing solutions Return to Church program being initiated in Orlando, Fla. area REHOVOT, Israel, SINGAPORE and NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of
-
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
5/18/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. (
-
ORYZON Announces Enrollment of First Patient in ESCAPE: a Phase II Clinical Trial with Vafidemstat in Severely Ill COVID-19 PatientsESCAPE study to recruit 40 patients
5/18/2020
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients. The study, named ESCAPE (Nº EudraCT: 2020-001618-39), is an open-label, randomized, double arm Phas
-
BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales
5/18/2020
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales
-
Agilent PD-L1 Assay Receives FDA Approval for Use as a Companion Diagnostic
5/18/2020
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer (NSCLC). Now, physicians will be able to use the PD-L1 IHC 28-8 pharmDx assay as an aid in identifying patients with metastatic NSCLC
-
Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
5/18/2020
Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 5,416,667 shares of its common stock at a price to the public of $60.00 per share.
-
Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer
5/18/2020
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18, 2020
-
MagnaCare and BioReference Laboratories Bring COVID-19 Antibody Testing to New York Labor Groups
5/18/2020
MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaborati
-
Cellect Biotechnology's ApoGraft™ to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases
5/18/2020
Signs Development Agreement with International Consortium; Royalties Will be Based on Commercialization of Future Products Clinical Results in GvHD Studies May be Beneficial in COVID-19 and CAR-T Cytokine Storm manifestations [18-May-2020] TEL AVIV, Israel , May 18, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative tec
-
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock
5/18/2020
Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has priced the previously announced underwritten public offering of 2,275,000 shares of its common stock, at a public offering price of $55.00 per share.
-
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027
5/18/2020
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to offer, subject to market and other conditions, shares of common stock and convertible senior notes due 2027
-
Oculis Reports Positive Top-line Data From SKYGGN (Phase 2) Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery
5/18/2020
- OCS-01 meets primary endpoints demonstrating superior efficacy and safety vs vehicle in the treatment of inflammation and pain following cataract surgery with a once-daily regimen - SKYGGN is the second positive trial with OCS-01 highlighting its potential for treating both front-of-the-eye and retinal diseases such as DME - Positive results validate the Solubilizing NanoParticle (SNP) formulation technology in developing topical treatments for front-of-the-eye with less fr
-
Thermo Fisher Scientific's Support of COVID-19 Response Continues to Expand with U.S. Government Contract for Products Used in Sample Collection
5/18/2020
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has received a contract from the U.S. government to provide highly specialized viral transport media (VTM) for COVID-19 sample collection. The VTM is used during collection of patient samples for proper transport to laboratories that can test for the presence of the virus.
-
Zebra Medical Vision Secures its 5th FDA Clearance, Making Its Vertebral Compression Fractures AI Solution Available in the U.S.
5/18/2020
Zebra-Med is the first AI startup securing FDA clearance for a population-health product helping health providers close the COVID-19-induced care gaps by identifying more patients at risk of osteoporosis, which costs $52B in the U.S. alone. Zebra-Med has also received its fourth U.S. patent in its bone health series, measuring potential risk for vertebral fractures KIBBUTZ SHEFAYIM, Israel--( BUSINESS WIRE )-- Zebra Medical Vision , the deep-learning
-
Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020
5/18/2020
PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and will continue to do so.
-
MacuHealth Congratulates Dr Paul Bernstein and the Bernstein Laboratory for Their Recent Publication in PNAS
5/18/2020
MacuHealth LLC would like to congratulate Dr Paul Bernstein and the Bernstein Laboratory for their recent publication in PNAS https://www.ncbi.nlm.nih.gov/pubmed/32409609
-
Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan
5/18/2020
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, announced today that its collaboration partner, Japan Tobacco, Inc. (JT), has filed a supplemental New Drug Application (NDA) with the Pharmaceuticals and Medic